BioStock: BioInvent’s CMO on new positive data with BI-1206
BioInvent has presented additional positive interim data from the company’s phase I/IIa clinical trial with drug candidate BI-1206 for immunotherapy treatment in patients with non-Hodgkin’s lymphoma. Biostock reached out to the company’s Chief Medical Officer, Andres McAllister, who is excited about seeing clinical responses this early in the trial. He is also very impressed by the quality and long duration of the responses.
Read the full interview with Andres McAllister at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/